Janus Henderson Group PLC Increases Holdings in Tyra Biosciences, Inc. $TYRA

Janus Henderson Group PLC lifted its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 32.5% during the first quarter, HoldingsChannel.com reports. The firm owned 3,890,589 shares of the company’s stock after purchasing an additional 955,147 shares during the quarter. Janus Henderson Group PLC owned approximately 0.07% of Tyra Biosciences worth $148,867,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Hilton Head Capital Partners LLC bought a new position in Tyra Biosciences in the 1st quarter worth about $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Tyra Biosciences during the 4th quarter valued at about $51,000. Chung Wu Investment Group LLC bought a new stake in shares of Tyra Biosciences during the fourth quarter valued at about $53,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after buying an additional 1,668 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group started coverage on shares of Tyra Biosciences in a research report on Monday, April 6th. They issued a “buy” rating and a $50.00 price objective for the company. JonesTrading started coverage on shares of Tyra Biosciences in a research note on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Tyra Biosciences in a research note on Thursday, May 14th. Wolfe Research began coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

Tyra Biosciences Stock Down 3.6%

NASDAQ:TYRA opened at $31.88 on Friday. The stock has a market cap of $1.90 billion, a P/E ratio of -14.62 and a beta of 0.76. The business’s 50-day moving average price is $30.48 and its two-hundred day moving average price is $32.66. Tyra Biosciences, Inc. has a twelve month low of $9.96 and a twelve month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, equities research analysts expect that Tyra Biosciences, Inc. will post -2.68 EPS for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.